To evaluate the Safety and efficacy of Unani formulations in Joint Pain

Validation of Analgesic Effect of Unani Pharmacopoeial formulation- Habb-e- SÅ«ranjÄ?n & Raughan-e- SÅ«ranjÄ?n in patients of Wajaâ??-ul- MafÄ?sil (Joint Pain)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/12/004197

Enrollment

540

Registered

2013-12-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M255- Pain in joint Health Condition 2: null- Wajaâ??-ul- MafÄ?sil (Joint Pain)

Interventions

Intervention1: Habb-e- SÅ«ranjÄ?n (Pills) & Raughan-e- SÅ«ranjÄ?n (Oil): Habb-e- SÅ«ranjÄ?n -2 Pills TDS after meal/ with milk Raughan-e- SÅ«ranjÄ?n- Local application (morning & Evening) Duration

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex in the age group of 18-65 2. Patients of Wajaâ??-ul- MafÄ?sil (Joint Pain) presenting joint pain (single/ multiple joints) with or without any one of the following symptoms/signs: • Tenderness • Swelling • Restriction of movement

Exclusion criteria

Exclusion criteria: Patients will be excluded if they meet any of the following criteria: 1. Patients having disorders requiring long term treatment like Diabetes Mellitus, Hypertension etc. 2. H/O Addictions (Alcohol, drugs). 3. Pregnant and lactating women 4.Known cases of Hepatic, Renal or Cardiac ailments

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Wajaâ??-ul-MafÄ?sil (Joint Pain)Timepoint: 2 WEEKS	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: 2 WEEKS	—

Countries

India

Contacts

Public ContactDR ABDUL HANNAN

Central Council for Research in Unani Medicine (CCRUM),

ccrum605@gmail.com011-28521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026